Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
$46.3K Sell
200
-50,600
-100% -$10.3M ﹤0.01% 738
2025
Q2
$9.43M Sell
50,800
-6,800
-12% -$1.26M 0.36% 63
2025
Q1
$12.1M Buy
57,600
+20,300
+54% +$3.95M 0.5% 36
2024
Q4
$6.63M Buy
37,300
+26,400
+242% +$4.85M 0.24% 99
2024
Q3
$2.15M Sell
10,900
-41,500
-79% -$7.75M 0.07% 312
2024
Q2
$8.99M Buy
52,400
+43,400
+482% +$7.19M 0.32% 69
2024
Q1
$1.64M Buy
+9,000
New +$1.55M 0.05% 440

Other funds holding ABBV

Point72 (DIFC)'s ABBV Position: Q3 2025 in Review

Point72 (DIFC) reduced its AbbVie (ABBV) stake by 75% in Q3 2025, selling an estimated $14.3M and leaving 23,416 shares worth $5.42M. The position accounts for 0.36% of the portfolio, ranked #72.

Point72 (DIFC) first reported a position in ABBV in Q2 2025 and has held it in 2 quarters since. The position peaked at $17.4M in Q2 2025. 3,906 funds tracked by Wall St. Rank hold ABBV as of Q3 2025.

  • Point72 (DIFC) held 23,416 shares of AbbVie worth $5.42M as of Q3 2025.
  • Point72 (DIFC) sold 70,451 AbbVie shares in Q3 2025, an estimated $14.3M.
  • AbbVie made up 0.36% of Point72 (DIFC)'s portfolio in Q3 2025, its #72 holding.
  • Point72 (DIFC) first reported a position in AbbVie in Q2 2025 and has held it in 2 quarters since.
  • Point72 (DIFC)'s AbbVie position peaked at $17.4M in Q2 2025.
  • 3,906 funds tracked by Wall St. Rank held AbbVie as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.